BR112014007127A2 - métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit - Google Patents

métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit

Info

Publication number
BR112014007127A2
BR112014007127A2 BR112014007127A BR112014007127A BR112014007127A2 BR 112014007127 A2 BR112014007127 A2 BR 112014007127A2 BR 112014007127 A BR112014007127 A BR 112014007127A BR 112014007127 A BR112014007127 A BR 112014007127A BR 112014007127 A2 BR112014007127 A2 BR 112014007127A2
Authority
BR
Brazil
Prior art keywords
a1pi
onset
delay
symptoms
progression
Prior art date
Application number
BR112014007127A
Other languages
English (en)
Portuguese (pt)
Inventor
Garlinghouse Les
Forshag Mark
Waltrip Royce
Barnett William
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of BR112014007127A2 publication Critical patent/BR112014007127A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014007127A 2011-12-30 2012-11-22 métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit BR112014007127A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161581708P 2011-12-30 2011-12-30
PCT/IB2012/056616 WO2013098672A2 (en) 2011-12-30 2012-11-22 Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations

Publications (1)

Publication Number Publication Date
BR112014007127A2 true BR112014007127A2 (pt) 2017-04-04

Family

ID=47470050

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007127A BR112014007127A2 (pt) 2011-12-30 2012-11-22 métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit

Country Status (18)

Country Link
US (1) US9421248B2 (enExample)
EP (1) EP2758065B1 (enExample)
JP (4) JP2015504051A (enExample)
KR (1) KR20140108516A (enExample)
CN (2) CN107596359A (enExample)
AR (2) AR088971A1 (enExample)
AU (1) AU2012337241B2 (enExample)
BR (1) BR112014007127A2 (enExample)
CA (1) CA2844878C (enExample)
CL (1) CL2014000722A1 (enExample)
ES (1) ES2887358T3 (enExample)
IL (1) IL231109B (enExample)
MX (1) MX351189B (enExample)
MY (1) MY166314A (enExample)
RU (1) RU2635482C2 (enExample)
SG (2) SG10201610913PA (enExample)
UY (1) UY34465A (enExample)
WO (1) WO2013098672A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160054475A (ko) * 2013-08-05 2016-05-16 제라드 뵈르만 흡연의 해로운 영향을 감소시키는 신규의 수단
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
RS65152B1 (sr) * 2015-02-05 2024-02-29 Canem Holdings Llc Preparati za lečenje granulomatoze sa poliangiitisom
WO2018154568A1 (en) 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
US10663434B2 (en) * 2017-03-31 2020-05-26 Sonix, Inc. Wafer chuck
WO2020014326A1 (en) * 2018-07-10 2020-01-16 Ciancone Christopher V Breath measurement device
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
TW202122086A (zh) * 2019-08-23 2021-06-16 韓商Ｐｈ製藥公司 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
US20230302104A1 (en) * 2020-05-01 2023-09-28 Atlas Biotechnology S.A. Treatment and/or prevention of a disease or a syndrome related to a virus infection

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE395611B (sv) 1975-12-12 1977-08-22 Draco Ab Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser
SE411705B (sv) 1976-11-09 1980-02-04 Draco Ab Anordning for generering av en avskermad, vesentligen drivmedelsfri aerosol
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4667688A (en) 1983-11-28 1987-05-26 Francisco Roig Mini pack of cigarettes
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
EP0169114B1 (fr) 1984-06-19 1991-01-16 Transgene S.A. Dérivés de l'alpha 1-antitrypsine humaine et procédé pour leur préparation
US4697003A (en) 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US5093316A (en) 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
MX9605717A (es) 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
AU6884396A (en) 1995-09-07 1997-03-27 Ppl Therapeutics (Scotland) Ltd Purification of alpha-1 proteinase inhibitor
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
OA11529A (en) 1998-03-16 2004-05-07 Inhale Therapeutic Syst Aerosolized active agent delivery.
US6093804A (en) 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
EP1366175B1 (en) 2000-12-18 2008-01-23 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
PT1664123E (pt) 2003-09-22 2008-07-16 Kamada Ltd Preparação em larga escala de um inibidor da alfa-1 proteinase e sua utilização
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
EP1737499A4 (en) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
EP1981572B1 (en) * 2006-02-09 2012-11-21 Kamada Ltd. Pulmonary delivery of alpha-i proteinase inhibitor
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
EP2321336A1 (en) 2008-07-18 2011-05-18 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
AU2010315325B2 (en) 2009-11-03 2014-11-27 Grifols Therapeutics Inc. Composition, method, and kit for alpha-1 proteinase inhibitor

Also Published As

Publication number Publication date
JP2015504051A (ja) 2015-02-05
JP2017039745A (ja) 2017-02-23
SG10201610913PA (en) 2017-02-27
JP2018104439A (ja) 2018-07-05
ES2887358T3 (es) 2021-12-22
IL231109B (en) 2018-02-28
AR116887A2 (es) 2021-06-23
EP2758065A2 (en) 2014-07-30
CL2014000722A1 (es) 2014-10-10
CN103889436A (zh) 2014-06-25
US9421248B2 (en) 2016-08-23
CN107596359A (zh) 2018-01-19
JP2019135243A (ja) 2019-08-15
WO2013098672A2 (en) 2013-07-04
CA2844878C (en) 2017-11-28
CA2844878A1 (en) 2013-07-04
IL231109A0 (en) 2014-04-30
RU2635482C2 (ru) 2017-11-13
US20150011460A1 (en) 2015-01-08
NZ621596A (en) 2016-08-26
MX351189B (es) 2017-10-04
MY166314A (en) 2018-06-25
AR088971A1 (es) 2014-07-23
KR20140108516A (ko) 2014-09-11
RU2014106758A (ru) 2015-08-27
WO2013098672A3 (en) 2013-10-24
MX2014001764A (es) 2014-04-30
AU2012337241B2 (en) 2016-10-13
UY34465A (es) 2013-07-31
EP2758065B1 (en) 2021-06-23
AU2012337241A1 (en) 2013-07-18
SG2014012066A (en) 2014-09-26
HK1198918A1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
BR112014007127A2 (pt) métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit
BR112015025256A2 (pt) cepas probióticas para uso no tratamento ou prevenção da osteoporose
CU20140082A7 (es) Pirimidinas y triazinas fusionadas sustituidas y sus uso
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
PH12015501108A1 (en) Treatment of pulmonary disease
CA2897464C (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
BR112014027165A2 (pt) antagonistas de st2l e métodos de uso
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
BR112015025854A2 (pt) flagelina de roseburia e modulação imunológica
NZ701700A (en) Bicyclically substituted uracils and the use thereof
AU2014212471A8 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
BR112016023754A2 (pt) ?uso de lactobacillus paracasei para promover recuperação da diversidade da microbiota intestinal após disbiose?
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
EA201691314A1 (ru) Терапевтические способы и композиции
BR112015024479A2 (pt) composição cosmética, farmacêutica ou alimentícia, método de tratamento cosmético, extrato, uso de um extrato e dos carotenoides
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112017013999A2 (pt) ?composição derivada de uma bifidobactéria?
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
UY33219A (es) Cetoenoles cíclicos para terapias
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina
BR112015025697A2 (pt) cepa do vírus vaccinia mutante, uso da cepa do vírus vaccinia mutante, método para a produção de um produto de gene recombinante e produto de gene recombinante
BR112014030547A2 (pt) composição farmacêutica
BR112015027218A2 (pt) tratamento eficaz de nsclc e marcador clínico preditivo da responsividade de um tumor a um tratamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2802 DE 17/09/2024.